Industry

SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Ulcerative Colitis Market Forecast – Epidemiology & Pipeline Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 … [Read more…]

 Conference Call to be Held on Thursday, September 8, 2022 at 4:00 p.m. (EDT) DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross … [Read more…]

Nexa3D creates key dental leadership roles in Europe, focused on expanding access to the latest dental technology Bracon Dental joins Nexa3D Dental reseller network, bringing ultrafast dental 3D printing capabilities to the United Kingdom First desktop XiP installation in a dental business signals rising demand for chair-side 3D printing capabilities   VENTURA, Calif.–(BUSINESS WIRE)–Ultrafast industrial … [Read more…]

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 … [Read more…]

LEWISVILLE, Texas–(BUSINESS WIRE)–CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry, today announced its latest updates to its CareView Patient Safety System®, Version 5.6, which includes system integration with Vocera and Hillrom, paving the way for a new paradigm in clinical workflow management. With these integrations, safety … [Read more…]

New funding round led by Nina Capital enables Healee to empower unique digital health models and accelerate telehealth adoption TAMPA, Fla.–(BUSINESS WIRE)–#custom—Healee, providing highly configurable digital health technology, announced today that it has raised $2M in a seed round led by Nina Capital, with the participation of Calm/Storm Ventures, KAYA VC and existing investor Eleven … [Read more…]

Cotiviti and health plan executives will discuss how to intelligently drive member interventions and achieve premium accuracy SALT LAKE CITY–(BUSINESS WIRE)–Cotiviti, a leader in data-driven healthcare solutions, will present on optimizing health plan risk adjustment programs at the RISE West conference in Los Angeles, taking place August 31–September 2, 2022. Cotiviti’s RaeAnn Grossman, executive vice … [Read more…]

HENDERSON, Nev.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today announced the appointment of James Messina as a non-Executive Director to its board. Mr. Messina is a Co-Founder and General Partner of Seattle Hill Ventures and x4 Capital Partners, which invest in, and support, startup ventures by … [Read more…]

– Clinical milestone marks initiation of first ever novel psilocybin analog to enter clinical development – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for … [Read more…]